The Analysis Of The Efficacy Of Infliximab Treatment In 36 Cases Of Active Crohn’s Disease

Objective:The aim of the study was to assess the efficacy and safety of infliximab treatment in 36 patients with active Crohn’s Disease.Methods:The study included 36 patients with active Crohn’s disease who received infliximab infusion.Data from clinical records were retrospectively reviewed in The First Affiliated Hospital of Soochow University from June 2009 to December 2015.We evaluated the condition of clinnical efficacy,mucosal healing,fistula closure,laboratory index and the safety before and after treatment.Results:(1)The 36 patients comprised 27(75.0%)men and 9(25.0%)women with a mean age of 28.8±6.5 years,and the median disease duration was 14.0(8.0,38.8)months.(2)At week 14 and week 30,the median C-reactive protein was 5.6(1.8,9.3)mg/L and 4.0(1.4,11.9)mg/L,compared with 12.8(8.5,22.4)mg/L before the treatment(Z=-3.319,P<0.05;Z=-2.921,P<0.05).The ESR,platelet count decreased significantly before treatment as well.The body mass index,albumin and hemoglobin were significantly higher than those before treatment(P <0.05).(3)The median Crohn’s Disease activity index was 120.3(98,150)at week 14,which was significantly lower than that before the treatment(Z=-5.012,P<0.05).The proportion of clinical remission and clinical response at week 14 were 75.0% and 50.0%.At the same time,66.7%(6/9)of the 9 patients concomitanted with corticosteroids at baseline had achieved corticosteroid-free clinical remission.At week 30,the median Crohn’s Disease activity index was 109.0(92,158).There were still 72.2% and 61.1% people in clinical remission and clinical response.(4)Of the 36 patients,11 were assesd by colonoscopy at the end of the study.After 30 weeks,the Simple endoscopic score for Crohn’s Disease was 1.8(1,5.2),as compared with 7.2(4.6,9)before the treatment.Mucosal healing had occurred in 6 of 11 patientsdoing the endoscopy.(5)There were 18 patients who had draining fistulas,the proportion of the complete response were 72.2%(13/18)at week 14 and 77.8%(14/18)at week 30.(6)Adverse events occurred in 13 patients.Infusion reactions occurred in 4 patients.Delayed allergy were reported by 4 patients,and 4 patients got an infection.One patient had liver function damage.Conclusion:Patients with active Crohn’s Disease who were treated with infliximab can get a clinincal remission,mucosal healing and fistula closure.It is safe in gengeral.